LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Journal Article > Research

Risk factors for visceral leishmaniasis relapse in immunocompetent patients following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India

Burza S, Sinha PK, Mahajan R, Lima MA, Mitra G, Verma N, Balsegaram M, Das P
Download
Download
Abstract
A proportion of all immunocompetent patients treated for visceral leishmaniasis (VL) are known to relapse; however, the risk factors for relapse are not well understood. With the support of the Rajendra Memorial Research Institute (RMRI), Médecins Sans Frontières (MSF) implemented a program in Bihar, India, using intravenous liposomal amphotericin B (Ambisome) as a first-line treatment for VL. The aim of this study was to identify risk factors for VL relapse by examining the characteristics of immunocompetent patients who relapsed following this regimen.
Countries
India
Subject Area
neglected tropical diseaseskala azar
DOI
10.1371/journal.pntd.0002536
Published Date
02-Jan-2014
PubMed ID
24392166
Languages
English
Journal
PLOS Neglected Tropical Diseases
Volume / Issue / Pages
Volume 8, Issue 1, Pages e2536
Issue Date
02-Jan-2014
Dimensions Badge